• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
EpiCast Report: Seasonal Influenza Vaccines Epidemiology Forecast to 2022 - Product Image

EpiCast Report: Seasonal Influenza Vaccines Epidemiology Forecast to 2022

  • ID: 2368704
  • November 2012
  • 69 pages
  • GlobalData

EpiCast Report: Seasonal Influenza Vaccines Epidemiology Forecast to 2022

Summary

Seasonal Influenza is a respiratory infection caused by influenza virus that results in mild to severe symptoms, such as fever, cold and cough. Vaccination has been shown to reduce influenza morbidity and mortality and high economic burden associated with influenza illness. Our epidemiologists expect seasonal influenza vaccination coverage rates for all countries but the UK and China to remain constant on average throughout the forecast period. Vaccine demand for all nine countries, on the other hand, is forecast to increase in the next decade. Overall, the US is projected to have the largest vaccine demand in the next decade at over 158 million, followed by Japan’s 37.4 million, whereas Spain is expected to have the lowest demand at just over eight million. Annual growth in vaccine demand for the next 10 years is highest in India (2.10%) and the UK (1.38%) and lowest in Japan (0.42%) and Germany (0.26%). By 2022, the US will have the highest vaccination coverage rate (46.1%) and India and China the lowest (both at 1.7%). Vaccine demand is expected to increase across all nine markets, READ MORE >

1
1

1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 Catalyst
2.2 Upcoming Related Reports
3 Epidemiology
3.1 Risk Factors and Comorbidities
3.2 Global Trends
3.2.1 United States
3.2.2 France
3.2.3 Germany
3.2.4 Italy
3.2.5 Spain
3.2.6 United Kingdom
3.2.7 Japan
3.2.8 India
3.2.9 China
3.3 Forecast Methodology
3.3.1 Sources Used
3.3.2 Forecast Assumptions and Methods
3.4 Epidemiological Forecast (2012–2022)
3.4.1 Seasonal Influenza Vaccination Coverage, N (%)
3.5 Discussion
3.5.1 Global Vaccination Coverage Outlook
3.5.2 Limitations in Analysis
3.5.3 Strengths of Analysis
4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologists
4.2.2 Reviewers
4.2.3 Global Director of Epidemiology and Clinical Trials Analysis
4.2.4 Global Head of Healthcare
4.3 About Us
4.4 About EpiCast
4.5 Contact Us
4.6 Disclaimer

1.1 List of Tables
Table 1: United States, Sources of Vaccination Coverage Data
Table 2: France, Sources of Vaccination Coverage Data
Table 3: Germany, Sources of Vaccination Coverage Data
Table 4: Italy, Sources of Vaccination Coverage Data, 2004–2006
Table 5: Italy, Sources of Vaccination Coverage Data, 2008–2012
Table 6: Spain, Sources of Vaccination Coverage Data
Table 7: United Kingdom, Sources of Vaccination Coverage Data
Table 8: Japan, Sources of Vaccination Coverage Data
Table 9: India and China, Sources of Vaccination Coverage Data
Table 10: Nine Markets, Seasonal Influenza Vaccination Coverage, N (%), 2012–2022

1.2 List of Figures
Figure 1: United States, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 2: France, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 3: Germany, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 4: Italy, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 5: Spain, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 6: United Kingdom, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 7: Japan, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 8: India, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 9: China, Seasonal Influenza Vaccination Coverage, N, 2001–2022
Figure 10: Nine Markets, Seasonal Influenza Vaccination Coverage, N, 2012–2022

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos